GlassScriptPhysician profile
Keerthi Reddy
NPI 1700296795
$6,623.81
in general payments reported to CMS, 2019-2025
29 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $341 · 2021: $1,066 · 2022: $1,404 · 2023: $65.01 · 2024: $1,270 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.84 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,509.98 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $768.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $656.17 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $582.32 | 2021-2025 | Dupixent |
| Csl Behring | $394.54 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.95 | 2021-2025 | Takhzyro, Hyqvia, Glassia |
| Amgen INC. | $334.09 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $329.07 | 2020-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $239.18 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $192.88 | 2020-2025 | |
| Galderma Laboratories, L.P. | $161.43 | 2025 | Nemluvio |
| Pfizer INC. | $148.54 | 2021-2025 | |
| Optinose US, INC. | $146.37 | 2020-2024 | |
| Kaleo, INC. | $127.60 | 2021-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $122.85 | 2021-2025 | Orladeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $83.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| Grifols USA, LLC | $75.71 | 2024-2025 | Xembify |
| Aimmune Therapeutics, INC. | $55.80 | 2021-2022 | |
| Pharming Healthcare, INC. | $49.52 | 2022-2025 | Ruconest |
| Phathom Pharmaceuticals, INC. | $34.59 | 2025 | Voquezna |
| Phadia US INC. | $34.41 | 2024-2025 | Immunocap |
| Horizon Therapeutics Plc | $29.81 | 2022 | |
| Incyte Corporation | $27.76 | 2025 | Opzelura |
| Shire North American Group INC | $23.64 | 2019 | |
| Lilly USA, LLC | $18.30 | 2025 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.87 | 2022 | |
| Organon LLC | $15.70 | 2025 | |
| Paratek Pharmaceuticals, INC. | $13.85 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keerthi Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.